Across TCGA pan-cancer cohorts, RNU6-696P RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of RNU6-696P’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where RNU6-696P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNU6-696P is over-expressed in tumor.
BRCA, STAD, and READ are the cancer types where RNU6-696P tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNU6-696P RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.